ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from ProKidney ( (PROK) ).
ProKidney has updated its investor presentation to reflect an increased total target enrollment of approximately 470 subjects for its Phase 3 REGEN-006 (PROACT 1) trial of rilparencel in advanced chronic kidney disease, while keeping statistical powering assumptions unchanged. The company still expects topline readout of the surrogate endpoint, eGFR slope, in the second quarter of 2027 and now projects topline data for the confirmatory composite time-to-event endpoint in the second half of 2029, milestones that frame the potential pathway toward accelerated and then full approval of its lead cell therapy and signal a long clinical and regulatory runway with implications for patients, investors and the broader kidney-disease treatment landscape.
The most recent analyst rating on (PROK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Neutral.
The score is primarily held down by weak financial performance (large operating losses, significant cash burn, and deeply negative equity). Technical indicators are broadly neutral with only modest longer-term support, valuation offers limited help due to negative earnings and no dividend, while recent corporate updates provide a constructive catalyst signal via regulatory alignment and manufacturing/clinical progress.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney is a biotechnology company focused on transforming chronic kidney disease care through rilparencel, a first-in-class autologous cell therapy derived from a patient’s own kidney cells. Targeting patients with advanced stage 3b/4 chronic kidney disease, particularly those with type 2 diabetes and at high risk of kidney failure, the company is building in-house manufacturing capacity and advancing multiple Phase 2 and Phase 3 clinical programs in a market with limited options to delay dialysis.
Average Trading Volume: 1,280,106
Technical Sentiment Signal: Sell
Current Market Cap: $595.7M
For an in-depth examination of PROK stock, go to TipRanks’ Overview page.
